About this item:

519 Views | 463 Downloads

Author Notes:

Corresponding Author: Margaret M. Cortese, MD, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta GA, mcortese@cdc.gov ; 404-639-1929

We acknowledge the important contributions of Michele M. Sturgeon, MPH, Slavica Mijatovic-Rustempasic, MS and Mathew D. Esona, PhD, in performing or supervising all of the laboratory testing at CDC (Atlanta), as well as Jessica Rudd, MPH (CDC, Atlanta), for her data management efforts.

We are grateful to the clinical microbiology laboratory staff at Egleston Children’s Hospital for their assistance in processing stool specimens collected.

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.


Research Funding:

Supported by the Emerging Infections Program, funded through the Centers of Disease Control and Prevention (U50CK000196-02).

L.I. received funding from National Center for Advancing Translations Sciences, National Institutes of Health, Clinical Research and Education Career Development Program (8R25MD007589-10).


  • Science & Technology
  • Life Sciences & Biomedicine
  • Pediatrics

Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children


Journal Title:

Journal of Pediatrics


Volume 172


, Pages 116-+

Type of Work:

Article | Post-print: After Peer Review


Objective Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care. Study design Children were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative. Results Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively. Conclusions Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.

Copyright information:

© 2016 Elsevier Inc.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote